目的:观察乌苯美司辅助化疗对乳腺癌患者免疫功能、生活质量、炎性因子以及不良反应的影响。方法:选取2016年1月至2018年12月于杭州市肿瘤医院接受治疗的女性乳腺癌患者102例为研究对象，采用随机数字表法分为观察组与对照组各51例。对照组予以单纯化疗，观察组在其基础上服用乌苯美司治疗。比较两组短期内临床疗效、治疗前及治疗3个月后免疫功能指标(CDn 3＋、CDn 4＋、CDn 8＋、CDn 4＋/CDn 8＋)、血清炎性因子[白细胞介素10(IL-10)、肿瘤坏死因子α(TNF-α)、C反应蛋白(CRP)]、生活质量[癌症患者生命质量测定量表(QLQ-C30)]水平变化，并记录治疗过程中的不良反应发生情况。n 结果:治疗后，观察组总有效率为64.71%，高于对照组的45.10%，差异有统计学意义(χn 2＝3.960，n P<0.05)；治疗3个月后，观察组患者CDn 3＋、CDn 4＋及CDn 4＋/CDn 8＋水平[(60.26±3.18)%、(43.17±2.35)%、(1.59±0.11)]均较治疗前[(52.25±3.15)%、(37.36±4.24)%、(1.11±0.19)]显著上升(n t＝18.074、12.592、22.853，均n P<0.05)，且明显高于同期对照组[(46.58±2.19)%、(33.26±2.28)%、(0.99±0.10)](n t＝25.302、21.614、28.823，均n P<0.05)；而观察组CDn 8＋水平[(27.16±2.14)%]较治疗前的(33.59±2.54)%显著下降(n t＝19.624，n P<0.05)，且明显低于同期对照组的(33.57±2.24)%(n t＝14.776，n P<0.05)；对照组CDn 3＋、CDn 4＋及CDn 4＋/CDn 8＋水平[(46.58±2.19)%、(33.26±2.28)%、(0.99±0.10)]均较治疗前[(52.25±3.34)%、(37.16±3.09)%、(1.11±0.12)]显著下降(n t＝14.644、10.373、7.791，均n P0.05)；治疗3个月后，观察组患者IL-10水平[(7.85±1.08)pg/L]较治疗前的(5.26±1.48)pg/L显著上升(n t＝14.450，n P<0.05)，而TNF-α、CRP水平[(5.26±1.59)ng/L、(9.63±1.55)mg/L]较治疗前[(10.16±2.12)ng/L、(43.26±6.06)mg/L]均显著下降(n t＝18.864、63.119，均n P0.05)；治疗3个月后，观察组患者躯体功能、角色功能、情绪功能、认知功能、社会功能评分分别为(70.46±7.42)分、(74.97±7.55)分、(72.13±8.25)分、(63.43±6.75)分、(69.24±5.91)分，较治疗前的(50.42±7.95)分、(55.14±6.31)分、(55.15±7.31)分、(48.21±8.33)分、(48.55±5.73)分均有显著上升(n t＝18.623、20.435、15.586、14.415、21.440，均n P<0.05)，对照组患者躯体功能、角色功能、情绪功能、认知功能、社会功能等各项评分分别为(63.17±7.01)分、(67.10±7.22)分、(64.41±7.95)分、(52.93±8.14)分、(60.51±8.34)分，较治疗前的(51.43±6.65)分、(55.34±6.66)分、(55.15±7.64)分、(49.13±8.41)分、(47.13±7.45)分均显著上升(n t＝12.275、12.101、8.484、3.279、12.103，均n P<0.05)，且观察组各项评分均明显高于对照组(n t＝5.100、5.380、4.812、7.091、6.099，均n P<0.05)；观察组患者不良反应总发生率为11.76%，明显低于对照组的35.29%(χn 2＝7.846，n P<0.05)。n 结论:乌苯美司辅助化疗可明显改善乳腺癌患者免疫功能，提升患者生活质量，显著降低炎性因子水平及化疗时的不良反应，安全有效。“,”Objective:To observe the effects of ubenimex adjuvant chemotherapy on adverse reactions, quality of life, inflammatory cytokines and immune function in patients with breast cancer.Methods:A total of 102 breast cancer patients treated in Hangzhou Cancer Hospital from January 2016 to December 2018 were selected in the research, and they were divided into observation group and control group according to the random number table method, with 51 cases in each group.The control group was given chemotherapy alone, and the observation group was treated with ubenimex on the basis of the control group.The short-term clinical efficacy, immune function indicators (CDn 3+, CDn 4+, CDn 8+, CDn 4+/CDn 8+), serum inflammatory factors[interleukin-10 (IL-10), tumor necrosis factor α (TNF-α), C-reactive protein (CRP)] and quality of life[Quality of Life Questionnaire-Core 30 (QLQ-C30)] before treatment and after 3 months of treatment were compared between the two groups, and the occurrence of adverse reactions were recorded during treatment.n Results:After treatment, the total effective rate in the observation group was higher than that in the control group (64.71% vs.45.10%) (χn 2=3.960, n P<0.05). After 3 months of treatment, the CDn 3+, CDn 4+ and CDn 4+/CDn 8+ levels in the observation group were significantly higher than those before treatment[(60.26±3.18)%, (43.17±2.35)%, (1.59±0.11) vs.(52.25±3.15)%, (37.36±4.24)%, (1.11±0.19)](n t=18.074, 12.592, 22.853, all n P<0.05), which were significantly higher than those in the control group [(46.58±2.19)%, (33.26±2.28)%, (0.99±0.10)] (n t=25.302, 21.614, 28.823, all n P<0.05). The CDn 8+ level in the observation group was significantly lower than that before treatment[(27.16±2.14)% vs.(33.59±2.54)%](n t=19.624, n P<0.05), which was significantly lower than that in the control group [(33.57±2.24)%] (n t=14.776, n P<0.05). The CDn 3+, CDn 4+ and CDn 4+/CDn 8+ levels in the control group were significantly lower than those before treatment[(46.58±2.19)%, (33.26±2.28)%, (0.99±0.10) vs.(52.25±3.34)%, (37.16±3.09)%, (1.11±0.12)](n t=14.644, 10.373, 7.791, all n P0.05). After 3 months of treatment, the IL-10 level in the observation group was significantly higher than that before treatment[(7.85±1.08)pg/L vs.(5.26±1.48)pg/L](n t=14.450, n P<0.05), while the TNF-α and CRP levels were significantly lower than those before treatment[(5.26±1.59)ng/L, (9.63±1.55)mg/L vs.(10.16±2.12)ng/L, (43.26±6.06)mg/L] (n t=18.864, 63.119, all n P0.05). After 3 months of treatment, the scores of physical function, role function, emotional function, cognitive function and social function in the observation group were significantly higher than those before treatment[(70.46±7.42)points, (74.97±7.55)points, (72.13±8.25)points, (63.43±6.75)points, (69.24±5.91)points vs.(50.42±7.95)points, (55.14±6.31)points, (55.15±7.31)points, (48.21±8.33)points, (48.55±5.73)points](n t=18.623, 20.435, 15.586, 14.415, 21.440, all n P<0.05), and the above scores in the control group were significantly higher than those before treatment[(63.17±7.01)points, (67.10±7.22)points, (64.41±7.95)points, (52.93±8.14)points, (60.51±8.34)points vs.(51.43±6.65)points, (55.34±6.66)points, (55.15±7.64)points, (49.13±8.41)points, (47.13±7.45)points](n t=12.275, 12.101, 8.484, 3.279, 12.103, all n P<0.05), and the scores in the observation group were significantly higher than those in the control group (n t=5.100, 5.380, 4.812, 7.091, 6.099, all n P<0.05). The total incidence of adverse reactions in the observation group was significantly lower than that in the control group (11.76% vs.35.29%) (χn 2=7.846, n P<0.05).n Conclusion:Adjuvant chemotherapy with ubenimex can significantly improve the immune function of breast cancer patients, enhance the quality of life, and can significantly reduce the levels of inflammatory factors and adverse reactions during chemotherapy, and it is safe and effective.